Comparative Efficacy and Tolerability of Lercanidipine and S-Isomer of Amlodipine in Patients with Essential Hypertension Associated with Abdominal Obesity

S.N. Koval, V.V. Bozhko, L.A. Resnik, I.A. Snegurskaya, S.V. Salnikova

Abstract


The aim of the work was a comparative study of the clinical efficacy and tolerability of S-isomer of amlodipine and lercanidipine in patients with essential hypertension (EH) and abdominal obesity (AO).
It was shown that monotherapy with S-amlodipine and lercanidipine are effective types in treating mild and moderate forms of EH, including that of associated with AO. However, treatment with lercanidipine in significantly greater number of cases leads to achievement of target blood pressure as compared to S-amlodipine. Lercanidipine monotherapy resulted in a significant decrease in the level of insulin resistance and microalbuminuria in the examined patients, while the S-amlodipine monotherapy did not lead to significant positive changes in these indicators. We revealed a reliable lower incidence of any adverse events in patients with EH and AO under the influence of lercanidipine monotherapy as compared with S-amlodipine.
Treatment with lercanidipine caused significantly lower incidence of edema of the lower limbs in patients with EH and AO than racemic amlodipine and S-amlodipine.


Keywords


essential hypertension; abdominal obesity; edema of the lower extremities; S-amlodipine

References


Рекомендації Української асоціації кардіологів із профілактики та лікування артеріальної гіпертензії. — П’яте видання, скорочене. — К.: ННЦ «Інститут кардіології ім. М.Д. Стражеска», 2011. — 45 с.

Арсеньева К.Е. Применение амлодипина в кардиологической практике // РМЖ. — 2009. — № 17 (8). — С. 610-613.

Морозова Т.Е., Захарова В.Л. Место амлодипина в кардиологической практике // Лечащий врач. — 2008. — № 2. — С. 14-17.

Воронков Л.Г. Клиническое использование хиральных молекул как новое направление в кардиоваскулярной медицине // Здоров’я України. — 2007. — № 21/1 (додатковий). — С. 31-32.

Свищенко Е.П., Матова Е.А., Гулкевич О.В. Азомекс Н в лечении больных пожилого возраста с артериальной гипертензией // Здоров’я України. — 2010. — № 6.

Borghi C., Prandin M.G., Dormi A. et al. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial // Blood Press. — 2003. — Vol. 12 (Suppl. 1). — 1-8.

Cherubini A., Fabris F., Ferrari E. et al. Comparative effects of lercanidipine, lacidipine and nifidepine GITS on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study // Arch. Gerontol. Geriatr. — 2003. — V. 3. — P. 203-212.

Mancia G., De Backer G., Dominiczak A. et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2007) Guidelines for the management of arterial hypertension // Eur. Heart J. — 28 (12). — 1462-1536.

Policicchio D., Magliocca R., Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine // J. Cardiovasc. Pharmacol. — 1997. — Vol. 29 (Suppl. 2). — S31-35.

Soma M.R., Natali M., Donetti E. et al. Effect of lercanidipine its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits // Br. J. Pharmacol. — 1998. — Vol. 125. — 1471-1476.

Rachmani R., Levi Z., Zadok B.S. et al. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study // Clin. Pharmacol. Ther. — 2002. — Vol. 72 (3). — 302-307.

Angelico P., Guarneri L., Leonardi A. et al. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues // J. Pharmacol. — 1999. — Vol. 51. — 709-714.

Сиренко Ю.Н. Дигидропиридиновые антагонисты кальция — новый резерв снижения риска при артериальной гипертензии // Новости медицины и фармации. — 2010. — № 1 (306).

Taddei S., Virdis A., Ghiadoni L., Versari D., Salvetti G., Magagna A., Salvetti A. Calcium Antagonist Treatment by Lercanidipine Prevents Hyperpolarization in Essential Hypertension // Hypertension. — 2003. — 41. — 950-955.

Janaviciene S., Laucevicius A., Subkovas E., Petrulioniene Z., Kibarskis A., Ryliskyte L. Calcium antagonist lercanidipine improves endothelium — dependent vasodilatation of the brachial artery in patients with proved coronary vasospasm // Seminars in Cardiology. — 2005. — Vol. 11, № 1.

Sabbatini М., Leonardi A., Testa R., Vitaioli L., Amenta F. Effect of Calcium Antagonists on Glomerular Arterioles in Spontaneously Hypertensive Rats // Hypertension. — 2000. — 35. — 775-779.

Dalla Vestra M., Pozza G., Mosca A., Grazioli V., Lapolla A., Fioretto P., Crepaldi G. Влияние лерканидипина на уровень экскреции альбумина у гипертензивных больных со 2-м типом сахарного диабета в сравнении с рамиприлом // Медицина неотложных состояний. — 2006. — № 2 (3). — С. 72-78.




DOI: https://doi.org/10.22141/2224-1485.4.30.2013.86483

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru